Q BioMed Inc (NASDAQ:QBIO) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 2, 2016
Zacks Investment Research has downgraded Q BioMed Inc (NASDAQ:QBIO) to Sell in a statement released on 9/28/2016.
Having a price of $4.73, Q BioMed Inc (NASDAQ:QBIO) traded -3.01% lower on the day. With the last stock price up 40.66% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. QBIO has recorded a 50-day average of $3.61 and a two hundred day average of $3.21. Trade Volume was up over the average, with 120,392 shares of QBIO changing hands over the typical 108,766
Recent Performance Chart
Q BioMed Inc has with a one year low of $1.26 and a one year high of $6.00 and has a market capitalization of $0.
General Company Details For Q BioMed Inc (NASDAQ:QBIO)
Q BioMed, Inc., formerly ISMO Tech Solutions, Inc., is a biomedical acceleration and development company. The Company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company intends to acquire multiple assets over time and across a spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns through organic growth, out-licensing, sale or spin-off into new public companies. The Company holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of pain associated with metastatic bone cancer. Its asset, MAN-01, is indicated for the treatment of glaucoma. MAN-01 is in pre-clinical stage. The Company is assessing multiple biomedical assets in various areas of healthcare and drug development. It is pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.